WealthPLAN Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

WealthPLAN Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,017	Closed	-$168K	–	1186
2023 Q2	$168K	Sell	2,017 -85	-4%	-$7.11K	0.02%	319
2023 Q1	$160K	Buy	+2,102	New	+$174K	0.02%	346
2022 Q1	$227K	Sell	3,071 -562	-15%	-$51.9K	0.02%	361
2021 Q4	$339K	Sell	3,633 -8,116	-69%	-$979K	0.02%	302
2021 Q3	$1.35M	Buy	11,749 +187	+2%	+$24.1K	0.09%	143
2021 Q2	$1.45M	Sell	11,562 -52	-0.4%	-$6.84K	0.1%	128
2021 Q1	$1.51M	Sell	11,614 -139	-1%	-$20.8K	0.12%	118
2020 Q4	$1.91M	Buy	11,753 +507	+5%	+$64.9K	0.16%	100
2020 Q3	$1.39M	Buy	11,246 +314	+3%	+$35.2K	0.14%	104
2020 Q2	$1.22M	Buy	10,932 +132	+1%	+$13K	0.13%	106
2020 Q1	$1.07M	Buy	10,800 +12	+0.1%	+$1.06K	0.14%	101
2019 Q4	$1.06M	Buy	10,788 +40	+0.4%	+$3.46K	0.12%	105
2019 Q3	$905K	Sell	10,748 -238	-2%	-$19.8K	0.12%	112
2019 Q2	$919K	Sell	10,986 -37	-0.3%	-$3.16K	0.14%	111
2019 Q1	$909K	Sell	11,023 -257	-2%	-$21.9K	0.14%	113
2018 Q4	$977K	Sell	11,280 -1,065	-9%	-$85.8K	0.16%	103
2018 Q3	$944K	Buy	12,345 +296	+2%	+$28.7K	0.17%	99
2018 Q2	$1.15M	Buy	12,049 +560	+5%	+$51.5K	0.24%	93
2018 Q1	$1.01M	Buy	11,489 +344	+3%	+$31.4K	0.22%	94
2017 Q4	$946K	Buy	11,145 +54	+0.5%	+$4.52K	0.25%	93
2017 Q3	$960K	Buy	11,091 +564	+5%	+$45.2K	0.27%	76
2017 Q2	$812K	Buy	10,527 +9,655	+1,107%	+$685K	0.23%	80
2017 Q1	$58.4K	Buy	+872	New	+$58.6K	0.2%	98
2016 Q3	$689K	Sell	10,488 -753	-7%	-$46.6K	0.22%	66
2016 Q2	$603K	Buy	+11,241	New	+$616K	0.08%	169
2015 Q4	$914K	Buy	+13,015	New	+$888K	0.15%	108
2015 Q2	–	Sell	-13,260	Closed	-$997K	–	515
2015 Q1	$997K	Buy	+13,260	New	+$926K	0.46%	44

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

WealthPLAN Partners's XBI Position: Q3 2023 in Review

WealthPLAN Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2023, closing a stake of 2,017 shares — an estimated $168K sold.

WealthPLAN Partners first reported a position in XBI in Q1 2015 and held it in 27 quarters. The position peaked at $1.91M in Q4 2020. 677 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

WealthPLAN Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2023 after selling out during the quarter.
WealthPLAN Partners sold 2,017 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $168K.
WealthPLAN Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and held it in 27 quarters.
WealthPLAN Partners's State Street SPDR S&P Biotech ETF position peaked at $1.91M in Q4 2020.
677 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on WealthPLAN Partners's 13F filing for Q3 2023, filed 2 Nov 2023.